International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication monitoring and antibiotic re-treatment at infection re-occurrence in patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)
This study is investigating a new way to treat a rare type of eye cancer called Ocular Adnexal Marginal Zone Lymphoma (OAMZL). Researchers are using an antibiotic called doxycycline, which is believed to kill a specific germ that might be linked to this cancer. The main goal is to find out if this treatment can stop the cancer from getting worse or returning for at least two years. They will give doxycycline for a while, then check if the germ is gone. If the infection comes back, they will give the antibiotics again. Scientists also want to see how well people tolerate the treatment, its overall effect, and to understand more about the genetic changes in this cancer.
At a glance
What is this study about?
This research study is focused on a type of cancer that affects the area around the eye, called Ocular Adnexal Marginal Zone Lymphoma, or OAMZL for short. Sometimes, this type of cancer is linked to an infection with a specific germ called Chlamydophila psittaci.
The main idea behind this study is to see if giving a common antibiotic, doxycycline, can help treat this cancer by getting rid of this germ. The researchers believe that by eliminating the germ, they might be able to stop the cancer from growing or coming back. They will give the antibiotic for a period, then check to make sure the germ is gone. If it reappears, they will restart the antibiotic treatment.
The main thing the study wants to find out is how many patients treated this way are free from their cancer getting worse or returning after two years. They will also be looking at other important things, like how easy the treatment is for patients to handle, how effective it is overall, and if the antibiotic successfully gets rid of the infection. Additionally, the study aims to learn more about the biology of OAMZL, including genetic changes that might be connected to the infection and how patients respond to treatment.
Key takeaways
- This study is for a specific type of eye cancer called OAMZL.
- It uses an antibiotic, doxycycline, to treat a germ possibly linked to the cancer.
- The main goal is to see if this treatment stops the cancer from returning for two years.
- Participants will receive ongoing treatment and close monitoring.
- The study also aims to learn more about OAMZL and how it responds to treatment.
Who may be eligible?
To be considered for this study, you must have been recently diagnosed with Ocular Adnexal Marginal Zone Lymphoma (OAMZL). This is a specific type of cancer that affects the tissues around your eye.
Your cancer must also be classified as 'stage-IE', which means it's in its earliest stage and localized to one area.
Generally, participants need to be 18 years old or older. The study is open to both men and women.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Have I recently been diagnosed with Ocular Adnexal Marginal Zone Lymphoma (OAMZL)?
- Is my OAMZL classified as 'stage-IE'?
- Am I 18 years old or older?
- Am I willing to take an antibiotic for a long period?
What does participation involve?
If you decide to participate in this study, you will receive doxycycline, an antibiotic, over a prolonged period. This treatment aims to clear a specific infection that might be linked to your cancer. You'll have regular check-ups to see how you're responding to the treatment and to monitor for the infection. If the infection reappears, you will receive the antibiotic treatment again.
The study will involve several visits to the clinic for assessments, which may include physical examinations, blood tests, and potentially other diagnostic procedures to track your cancer and the infection. The exact number and frequency of visits will be explained by the study team. You will be monitored closely throughout the treatment period and then for a follow-up period to see how well the treatment has worked over two years. The total duration of your participation will extend over at least two years to track long-term results.
Potential risks and benefits
Locations (1)
- —UnverifiedItaly
Common questions
What is OAMZL?
OAMZL is a rare type of cancer that affects the tissues around your eye. It's also known as Ocular Adnexal Marginal Zone Lymphoma.
What is doxycycline?
Doxycycline is an antibiotic, a type of medicine used to treat bacterial infections.
Why use an antibiotic for cancer?
In this specific type of eye cancer (OAMZL), an infection with a germ called Chlamydophila psittaci is sometimes found. The study is testing if treating this infection with doxycycline can help treat the cancer itself.
What does 'progression-free survival' mean?
Progression-free survival means the length of time that a patient lives with the disease without it getting worse or coming back.
How long will the treatment last?
The doxycycline treatment will be given for a prolonged period, and your overall participation in the study to monitor results will last at least two years.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.